Meridian Launches New Air-Dryable qPCR Mix Enabling Direct Detection of RNA from Whole Blood Samples
By LabMedica International staff writers Posted on 08 Oct 2021 |
Meridian Bioscience, Inc. (Cincinnati, OH, USA) has launched its new Air-Dryable Direct RNA/DNA qPCR Blood Mix, an innovative master mix designed to develop room-temperature stable molecular diagnostic assays that directly amplify RNA from crude whole blood, serum, or plasma.
The new offering adds to the innovative portfolio of sample-specific master mixes that Meridian has created to help molecular diagnostic manufacturers develop assays faster. The ability of qPCR to screen directly from blood samples provides faster and highly sensitive detection of viral infections such as HIV, HBV, or HCV, but also bacterial infections, hereditary diseases, and forensic analyses. Blood can also be used as a non-invasive liquid biopsy for examining circulating tumor DNA, RNA, or cells, which is essential in cancer management, allowing prognosis, diagnosis, and monitoring following treatment. However, PCR inhibitors often found in blood samples can produce false-negative results or reduced limit-of-detection (LOD) unless costly and time-consuming DNA/RNA purification is used.
Meridian's new Air-Dryable Direct RNA/DNA qPCR Blood Mix can be used on crude samples and eliminates the need for an extraction step. It uses specialized enzymes and an advanced buffer formulation pre-optimized specifically for whole blood, serum, and plasma. The blood master mix was designed to be compatible with air-drying in an oven while maintaining the highest activity and sensitivity. Air-Dryable technology replaces the need for lyophilization with fast, simple, and inexpensive oven-drying procedures, making it ideal for manufacturing room-temperature stable, highly sensitive, and cost-effective molecular diagnostic assays.
"The Air-Dryable Direct RNA/DNA qPCR Blood Mix provides a diagnostic developer with a ready to use master mix that has already addressed all the complex inhibitors present in blood, allowing for the development of simpler and faster assays," said Diane Szydel, Vice President, Global Life Science Commercial Operations at Meridian. "In addition, Meridian's air-dryable technology overcomes the time and cost associated with cold storage or lyophilization, allowing manufacturers full control of their entire manufacturing workflow."
Related Links:
Meridian Bioscience, Inc.
Latest Molecular Diagnostics News
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access